VERDESO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VERDESO (VERDESO).
Clobetasol propionate is a highly potent corticosteroid that binds to glucocorticoid receptors, inducing the synthesis of lipocortins which inhibit phospholipase A2, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Hepatic metabolism via CYP3A4-mediated pathways |
| Excretion | Primarily biliary/fecal excretion (approximately 90%) as unchanged drug and metabolites; renal excretion accounts for <10%. |
| Half-life | Terminal elimination half-life is approximately 100 hours (range 70-140 hours), supporting once-weekly topical application. |
| Protein binding | >99% bound to plasma proteins, predominantly to albumin and lipoproteins. |
| Volume of Distribution | Very large (>100 L/kg) after systemic absorption, indicating extensive distribution into tissues, including skin and adipose. |
| Bioavailability | Topical: Approximately 1-2% systemically absorbed through intact skin; higher with occlusive dressings or diseased skin. |
| Onset of Action | Topical: Clinical improvement in plaque psoriasis typically observed within 2-4 weeks of once-daily application. |
| Duration of Action | After discontinuation, therapeutic effect may persist for several weeks; however, reapplication is needed weekly to maintain response. |
| Molecular Weight | 466.85 Da |
Topical: apply a thin layer of VERDESO (clobetasol propionate) foam, 0.05%, to affected areas twice daily (morning and night) for up to 2 weeks; maximum weekly dose should not exceed 50 g.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dose adjustment required for renal impairment; systemic absorption is minimal with topical use. |
| Liver impairment | No specific dose adjustment recommendations for hepatic impairment; use with caution due to potential increased systemic absorption if extensive areas are treated. |
| Pediatric use | Safety and efficacy in pediatric patients below 12 years have not been established; for children 12 years and older, same as adult dosing (apply twice daily for up to 2 weeks). Use the smallest amount needed. |
| Geriatric use | No specific dose adjustment required; use caution due to thinner skin and potential for increased systemic absorption; limit treatment to smallest amount and shortest duration necessary. |
| 1st trimester | Avoid use due to potential teratogenicity; topical corticosteroids are associated with orofacial clefts. |
| 2nd trimester | Use only if potential benefit justifies risk; may cause fetal growth restriction. |
| 3rd trimester | Avoid use; risk of fetal adrenal suppression and low birth weight. |
Clinical note
Comprehensive clinical and safety monograph for VERDESO (VERDESO).
| Placental transfer | Yes, topical corticosteroids cross the placenta; degree depends on potency and application area. Clobetasol propionate has high potency and potential for significant transfer. |
| Breastfeeding | Not recommended; systemic absorption may occur, and topical application near breast area could expose infant. Limited data suggest low levels in breast milk. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to clobetasol propionate or any componentUntreated bacterial, fungal, or viral skin infectionsRosaceaPerioral dermatitis
| Precautions | Systemic absorption can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, Local adverse reactions including skin atrophy, striae, telangiectasias, and secondary infections, Avoid use on face, axillae, or groin, Use with caution in pediatric patients due to increased skin surface-to-body weight ratio |
| Food/Dietary | No known food interactions; Verdeso is applied topically and minimal systemic absorption occurs. However, avoid topical application near the mouth until product dries to prevent ingestion. |
Loading safety data…
| Lactation Rating |
| L3 - Moderately Safe |
| Teratogenic Risk | VERDESO (clobetasol propionate) is a super-high potency topical corticosteroid. Systemic absorption is minimal with topical use but may be increased with application to large surface areas, under occlusion, or on broken skin. In pregnancy, no adequate and well-controlled studies exist. Based on animal studies and the known effects of corticosteroids, use during pregnancy should be avoided unless the potential benefit justifies the risk to the fetus. First trimester: There is a potential for increased risk of orofacial clefts (based on systemic corticosteroids), but data for topical use are insufficient. Second/third trimester: Chronic exposure may lead to fetal growth restriction and hypothalamic-pituitary-adrenal axis suppression. Use only if clearly needed and limit to small areas, avoid occlusion, and use for short duration. |
| Fetal Monitoring | Monitor for signs of maternal hypothalamic-pituitary-adrenal axis suppression (e.g., fatigue, hypotension, hypoglycemia) if large areas are treated or occlusion is used. Monitor fetal growth via ultrasound if used chronically during pregnancy. In the neonate, monitor for adrenal suppression (e.g., poor feeding, vomiting, lethargy) if maternal use was prolonged or high-dose. |
| Fertility Effects | Animal studies with clobetasol propionate at doses exceeding the maximum human topical application have shown no impairment of fertility. No human data are available on the effects of topical corticosteroids on fertility. It is unlikely that topical use at recommended doses impairs fertility, but systemic absorption from extensive use could theoretically affect reproductive function. |
| Clinical Pearls | Verdeso (desonide) is a low-potency topical corticosteroid. Use sparingly on thin skin areas like face and intertriginous zones due to increased absorption. Avoid prolonged use, especially in children, to prevent systemic side effects. Discontinue if irritation or sensitization occurs. May be used for mild to moderate atopic dermatitis and seborrheic dermatitis. |
| Patient Advice | Apply a thin layer to affected skin only, not to healthy skin. · Use exactly as prescribed; do not cover with bandages unless directed. · Avoid contact with eyes, mouth, and open wounds. · Wash hands after application unless treating hands. · Do not use for longer than prescribed; prolonged use may cause skin thinning or systemic effects. · Inform your doctor if condition worsens or does not improve after 2 weeks. · Keep out of reach of children; accidental ingestion may require medical attention. |